BRPI0509923A - processo para formação de cálcio de atorvastatina amorfa - Google Patents
processo para formação de cálcio de atorvastatina amorfaInfo
- Publication number
- BRPI0509923A BRPI0509923A BRPI0509923-4A BRPI0509923A BRPI0509923A BR PI0509923 A BRPI0509923 A BR PI0509923A BR PI0509923 A BRPI0509923 A BR PI0509923A BR PI0509923 A BRPI0509923 A BR PI0509923A
- Authority
- BR
- Brazil
- Prior art keywords
- amorphous atorvastatin
- formation process
- atorvastatin calcium
- atorvastatin
- calcium formation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
PROCESSO PARA FORMAçãO DE CáLCIO DE ATORVASTATINA AMORFA. Formação de atorvastatina amorfa compreende as etapas de dissolução de cálcio de atorvastatina em um solvente para formar uma solução, seguido pela adição da solução a uma mistura compreendendo um não solvente e um solvente hidroxílico para proporcionar atorvastatina amorfa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56294804P | 2004-04-16 | 2004-04-16 | |
PCT/IB2005/000884 WO2005100313A1 (en) | 2004-04-16 | 2005-04-04 | Process for forming amorphous atorvastatin calcium |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509923A true BRPI0509923A (pt) | 2007-09-18 |
Family
ID=34963002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509923-4A BRPI0509923A (pt) | 2004-04-16 | 2005-04-04 | processo para formação de cálcio de atorvastatina amorfa |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070225353A1 (pt) |
EP (1) | EP1742910A1 (pt) |
JP (2) | JP2007532622A (pt) |
KR (1) | KR100829268B1 (pt) |
CN (1) | CN1960972A (pt) |
AR (1) | AR048756A1 (pt) |
AU (1) | AU2005232959A1 (pt) |
BR (1) | BRPI0509923A (pt) |
CA (1) | CA2562844A1 (pt) |
IL (1) | IL178574A0 (pt) |
MX (1) | MXPA06011987A (pt) |
NO (1) | NO20065229L (pt) |
RU (1) | RU2330840C1 (pt) |
TW (1) | TW200538111A (pt) |
WO (1) | WO2005100313A1 (pt) |
ZA (1) | ZA200608632B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101039906A (zh) * | 2004-10-18 | 2007-09-19 | 特瓦制药工业有限公司 | 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法,所述有机溶剂为醇和酮和 /或酯的混合物 |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
US20100168201A1 (en) * | 2005-11-29 | 2010-07-01 | Biocan Limited | Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid Magnesium Salt (2:1) |
KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
CN101538237B (zh) * | 2008-05-30 | 2011-04-06 | 天津和美生物技术有限公司 | 阿伐他汀半钙盐丁酮共结晶物、其制备和作为HMG-CoA酶抑制剂的应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
EP0680320B1 (en) * | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
CZ294108B6 (cs) * | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
IL127058A (en) * | 1996-07-29 | 2001-07-24 | Warner Lambert Co | Process for the synthesis of protected esters of acid (S) - 4,3 dehydroxybutyric |
WO1999032434A1 (en) * | 1997-12-19 | 1999-07-01 | Warner-Lambert Export Limited | Process for the synthesis of 1,3-diols |
IN191236B (pt) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
US6605759B1 (en) * | 2000-12-22 | 2003-08-12 | Pioneer Hi-Bred International, Inc. | Soybean variety 95B34 |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
-
2005
- 2005-04-04 JP JP2007507860A patent/JP2007532622A/ja active Pending
- 2005-04-04 CA CA002562844A patent/CA2562844A1/en not_active Abandoned
- 2005-04-04 RU RU2006136902/04A patent/RU2330840C1/ru not_active IP Right Cessation
- 2005-04-04 AU AU2005232959A patent/AU2005232959A1/en not_active Abandoned
- 2005-04-04 US US11/578,084 patent/US20070225353A1/en not_active Abandoned
- 2005-04-04 EP EP05718356A patent/EP1742910A1/en not_active Withdrawn
- 2005-04-04 MX MXPA06011987A patent/MXPA06011987A/es not_active Application Discontinuation
- 2005-04-04 BR BRPI0509923-4A patent/BRPI0509923A/pt not_active IP Right Cessation
- 2005-04-04 WO PCT/IB2005/000884 patent/WO2005100313A1/en active Application Filing
- 2005-04-04 KR KR1020067022321A patent/KR100829268B1/ko not_active IP Right Cessation
- 2005-04-04 CN CNA2005800176879A patent/CN1960972A/zh active Pending
- 2005-04-14 AR ARP050101467A patent/AR048756A1/es not_active Application Discontinuation
- 2005-04-15 TW TW094112154A patent/TW200538111A/zh unknown
-
2006
- 2006-10-15 IL IL178574A patent/IL178574A0/en unknown
- 2006-10-16 ZA ZA200608632A patent/ZA200608632B/xx unknown
- 2006-11-14 NO NO20065229A patent/NO20065229L/no not_active Application Discontinuation
-
2008
- 2008-04-15 JP JP2008105757A patent/JP2008255117A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AR048756A1 (es) | 2006-05-24 |
US20070225353A1 (en) | 2007-09-27 |
AU2005232959A1 (en) | 2005-10-27 |
JP2007532622A (ja) | 2007-11-15 |
IL178574A0 (en) | 2007-02-11 |
CN1960972A (zh) | 2007-05-09 |
MXPA06011987A (es) | 2007-01-16 |
EP1742910A1 (en) | 2007-01-17 |
KR20060133061A (ko) | 2006-12-22 |
RU2330840C1 (ru) | 2008-08-10 |
KR100829268B1 (ko) | 2008-05-13 |
RU2006136902A (ru) | 2008-04-27 |
NO20065229L (no) | 2006-11-14 |
JP2008255117A (ja) | 2008-10-23 |
WO2005100313A1 (en) | 2005-10-27 |
TW200538111A (en) | 2005-12-01 |
CA2562844A1 (en) | 2005-10-27 |
ZA200608632B (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0717404A2 (pt) | Processo para produzir polímero modifcado, polímero modificado obtido pelo processo e composição de borracha de borracha contendo o mesmo | |
DK1881967T3 (da) | Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika | |
BRPI0706947B8 (pt) | método de preparação de uma composição de micropartícula | |
ATE536192T1 (de) | Vernetzte hyaluronsäure und kollagen und ihre verwendungen | |
JP2004169007A5 (pt) | ||
BRPI0519996A2 (pt) | processo para formar atorvastatina amorfa | |
EP1698937A3 (en) | Positive resist composition and pattern-forming method using the same | |
WO2007076062A3 (en) | Protein formulations with reduced viscosity and uses thereof | |
BRPI0803374A2 (pt) | compostos polihidróxi como agentes de extinção de polimerização | |
ME00996B (me) | Trans-klomifen za liječenje metaboličkog sindroma | |
BRPI0509923A (pt) | processo para formação de cálcio de atorvastatina amorfa | |
BR112012026357A2 (pt) | processo para a preparação de pirrolinas a partir de gama-nitrocetonas. uso das gama-intracetonas como pesticidas | |
CL2008003265A1 (es) | Compuestos derivados de heterociclos nitrogenados, supresores de la produccion de colageno; composicion farmaceutica que comprende dichos compuestos; y su uso para prevenir y/o tratar la fibrosis y/o los tumores. | |
BR112012033195A2 (pt) | método de dissolver materiais lignocelulósicos. | |
BRPI0921583A2 (pt) | Composição, uso de um sistema de solvente, processo para produzir uma composição, uso de uma composição, e, material de semente | |
DE602006017724D1 (de) | Salicylsäurederivate | |
WO2009138847A3 (en) | An improved process for the preparation of cefozopran | |
BRPI0819785A2 (pt) | Processo isento de solvente orgânico, composição, e , uso de uma composição | |
BRPI0915439B8 (pt) | composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição | |
BR112013014715B8 (pt) | processo para produzir um artigo oco polimérico | |
BRPI0908833A2 (pt) | Composição polimérica elastomérica biodegradável, processo para preparar uma composição polimérica, e, uso da composição polimérica. | |
BRPI0411313A (pt) | processo para formar atorvastatina amorfa | |
BRPI1010546B8 (pt) | processo para produzir composto, método para isolar e purificar cristais de solvato do composto, e, uso do composto | |
AR048040A1 (es) | Metodo de purificacion de mesotriona | |
AR051341A1 (es) | Proceso para la preparacion de derivados de [1,4,5]-oxadiazepina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |